Faculty:
Aaron E. Miller, MD
Medical Director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Professor of Neurology
Mount Sinai School of Medicine
New York, NY
Bruce A. Cohen, MD
Professor, Davee Department of Neurology and Clinical Neurosciences
Northwestern University, Feinberg School of Medicine
Chicago, IL
Andrew D. Goodman, M.D., FAAN
Professor of Neurology
Director, Multiple Sclerosis Center
Chief, Neuroimmunology Unit
Department of Neurology
University of Rochester Medical Center
Rochester, NY
Reviewers:
Ronald A. Codario, MD
Ronald Codario, MD, FACP, FNLA CCMEP (Recertification review on 11/13/15)
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears on this page and the next page.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Planning Committee and Faculty members report the following relationship(s) which are accurate at the time of original content release (December 30, 2013):
Aaron E. Miller, MD
Research Support: Acorda Therapeutics, Inc.; Biogen-IDEC; Genentech; Genzyme; Novartis; Osmotica; Questcor; Roche; Sanofi-Aventis
Consultant: Accordant Health Services; Acorda Therapeutics, Inc.; Biogen-IDEC; EMD Serono (Merck Serono); Genzyme/Sanofi-Aventis; Glaxo Smith Kline; Novartis; Nuron Biotech; ONO
Bruce A. Cohen, MD
Consulting Fees: Acorda Therapeutics, Inc.; Biogen-IDEC; EMD Serono; Genentech; Genzyme; Questcor; Sanofi-Aventis; Teva Neuroscience
Andrew D. Goodman, M.D., FAAN
Consulting Fees: Acorda Therapeutics, Inc.; Biogen-IDEC; Genzyme-Sanofi; GW Pharma; Mylan; Novartis; Teva Neuroscience
Contracted Research: Acorda Therapeutics, Inc.; Avanir; Biogen-IDEC; EMD Serono; Genzyme; Novartis; Sun Pharma; Takeda; Teva Neuroscience
Fred D. Lublin, MD, FAAN, FANA
Sources of Funding for Research: Acorda Therapeutics, Inc.; Biogen Idec; Novartis Pharmaceuticals Corp; Teva Neuroscience, Inc.; Genzyme; Sanofi; Celgene; NIH; NMSS
Consulting Agreements/Advisory Boards/DSMB: Bayer HealthCare Pharmaceuticals; Biogen Idec; EMD Serono, Inc.; Novartis; Teva Neuroscience; Actelion; Sanofi-Aventis; Acorda; Questcor; Roche, Genentech; Celgene; Johnson & Johnson; Revalesio; Coronado Bioscience, Genzyme, MedImmune; Bristol-Myers Squibb, Xenoport, Receptos; Forward Pharma
Co-Chief Editor: Multiple Sclerosis and Related Diseases
Current Financial Interests/Stock Ownership: Cognition Pharmaceuticals, Inc.
Clyde E. Markowitz, MD
Consulting Fees: Bayer Healthcare, Biogen-IDEC, Genentech, Genzyme, Questcor, Roche, Sanofi- Aventis, Teva Neuroscience
Mark Tullman, MD
Consulting Fees: Acorda Therapeutics, Allergan, Biogen Idec, Genzyme, Novartis, Teva
Speakers Bureau: Acorda Therapeutics, Biogen Idec, EMD Serono, Genzyme, Pfzer, Teva
Reviewer reports the following relationship(s):
Ronald A. Codario, MD
No relevant financial relationships to disclose.
Ronald Codario, MD, FACP, FNLA CCMEP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.